TSC-101 for Acute Myeloid Leukemia

(ALLOHA-2 Trial)

This trial tests a new treatment called TSC-101 for individuals with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). The researchers aim to determine if adding TSC-101, a specialized immune cell therapy, to standard care can improve outcomes after a specific type of stem cell transplant. Participants will receive either TSC-101 plus standard care or just standard care. This study suits those with AML or MDS who are HLA-A*02:01 positive and plan to undergo a reduced-intensity stem cell transplant from a specific type of donor. As a Phase 3 trial, it represents the final step before FDA approval, offering participants the opportunity to contribute to the potential availability of a new treatment.

Research has shown that TSC-101 is generally safe for people. Earlier studies revealed that this treatment had safety results similar to those observed after a blood cell transplant, a procedure that replaces damaged blood cells. These studies identified no new safety concerns. Patients who received TSC-101 tolerated it well, with side effects typical for such transplants. This suggests that TSC-101 is as safe as other treatments used in similar medical procedures.¹²³⁴⁵

TSC-101 is unique because it targets a specific genetic marker, HLA-A*02:01, in patients with Acute Myeloid Leukemia (AML). Unlike standard treatments like chemotherapy and stem cell transplantation that broadly attack cancer cells, TSC-101 is tailored to work with patients' immune systems, potentially offering a more personalized and effective approach. Researchers are excited because this precision targeting could reduce side effects and improve outcomes by enhancing the compatibility between donor cells and the patient's immune system.

Research has shown that TSC-101, which participants in this trial may receive, may effectively treat acute myeloid leukemia (AML). Studies have found that TSC-101 successfully replaces a patient's blood cells with healthy donor cells in 93% of AML patients. It also appears to reduce the chances of cancer recurrence and increase survival rates. TSC-101 targets and removes leftover cancerous blood cells after a stem cell transplant, helping to prevent the disease from returning. Early results suggest it can help patients remain cancer-free for longer periods. Participants in the control arm will receive the standard of care treatment without TSC-101.¹⁶⁷⁸⁹